Urolithin A attenuates ox-LDL-induced endothelial dysfunction partly by modulating microRNA-27 and ERK/PPAR-γ pathway

Mol Nutr Food Res. 2016 Sep;60(9):1933-43. doi: 10.1002/mnfr.201500827. Epub 2016 May 31.

Abstract

Scope: Endothelial dysfunction and inflammation are both common events occurring during the development of atherosclerosis. Previous studies have shown that urolithins, the intestinal microflora metabolites of ellagitannin, exhibit anti-inflammation and antioxidative properties. This study aims to investigate the protective effect of urolithin A (UA) on ox-LDL-induced (where ox-LDL is oxidized low-density lipoprotein) endothelial dysfunction and possible modes of action.

Methods and results: Human artery endothelial cells were incubated with 50 μg/mL ox-LDL and various concentrations of UA for 24 h. UA improved the productions of nitric oxide and endothelial nitric oxide synthase in a dose-dependent manner. UA markedly reduced the expressions of ICAM-1 (intercellular adhesion molecule 1) and MCP-1 (monocyte chemotactic protein 1) and further attenuated THP-1 (human acute monocytic leukemia cell line) cell adhesion. In addition, UA suppressed expressions of tumor necrosis factor α, interleukin 6, and endothelin 1, and increased PPAR-γ (peroxisome proliferators activated receptor gamma) mRNA expression. Moreover, UA decreased miR-27 expression, and overexpression of miR-27 by adding pre-miR-27 abolished the ability of UA to improve ox-LDL-induced PPAR-γ decrease. Furthermore, UA significantly downregulated phosphorylated ERK1/2 (where ERK is extracellular signal-regulated kinase) while decreasing interleukin 6 level and elevating PPAR-γ.

Conclusions: UA could alleviate endothelial dysfunction induced by ox-LDL partially through modulating miR-27 expression and ERK/PPAR-γ pathway.

Keywords: Atherosclerosis; ERK signal pathway; Endothelial dysfunction; MicroRNA-27; Urolithin A.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Adhesion / drug effects
  • Cell Line
  • Coumarins / pharmacology*
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / metabolism
  • Endothelium, Vascular / physiopathology
  • Humans
  • L-Lactate Dehydrogenase / metabolism
  • Lipoproteins, LDL / metabolism*
  • MAP Kinase Signaling System / drug effects
  • MicroRNAs / metabolism*
  • Monocytes / drug effects
  • Nitric Oxide / metabolism
  • Nitric Oxide Synthase Type III / metabolism
  • PPAR gamma / genetics
  • PPAR gamma / metabolism*
  • Protective Agents / pharmacology

Substances

  • Coumarins
  • Lipoproteins, LDL
  • MIRN27 microRNA, human
  • MicroRNAs
  • PPAR gamma
  • Protective Agents
  • oxidized low density lipoprotein
  • 3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-one
  • Nitric Oxide
  • L-Lactate Dehydrogenase
  • NOS3 protein, human
  • Nitric Oxide Synthase Type III